Literature DB >> 9263166

Adult onset Still's disease associated hemophagocytosis.

S Kumakura1, H Ishikura, S Munemasa, T Adachi, Y Murakawa, S Kobayashi.   

Abstract

Reactive hemophagocytosis is characterized by the activation of histiocytes with prominent hemophagocytosis in the reticuloendothelial system, and usually occurs in association with underlying disorders such as viral or bacterial infection and malignancy. We describe 3 cases of adult onset Still's disease (AOSD) who developed hemophagocytosis in bone marrow. Extensive studies could not identify any viral infection or other known underlying disorders for reactive hemophagocytosis except for active AOSD. Although the causative mechanisms of reactive hemophagocytosis in AOSD are not clear, our cases suggest the possibility of AOSD associated hemophagocytosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263166

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  A long story begun with a simple sore throat.

Authors:  Giuseppina Pisano; Paola Bonara; Paolo Rietti; Lorena Airaghi; Luigi Sinigaglia; Giovanni Boccoli; Larry Burdick; Marta del Medico; Edoardo Pulixi; Fabio Silini; Alessandra Gandolfi; Silvia Fargion
Journal:  Intern Emerg Med       Date:  2010-07-22       Impact factor: 3.397

Review 2.  Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature.

Authors:  J-B Arlet; Thi Huong D Le; A Marinho; Z Amoura; B Wechsler; T Papo; J-C Piette
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

3.  Reactive haemophagocytic syndrome in a patient with adult-onset Still's disease: beta-lactams as trigger?

Authors:  F Mearelli; P Vinci; M Gigli; C Casarsa; G Biolo
Journal:  Infection       Date:  2013-11-10       Impact factor: 3.553

4.  A study of haematological and bone marrow changes in symptomatic patients with human immune deficiency virus infection with special mention of functional iron deficiency, anaemia of critically ill and haemophagocytic lymphohistiocytosis.

Authors:  Jyoti Kotwal; Vikram Singh; Anupam Kotwal; Vibha Dutta; Velu Nair
Journal:  Med J Armed Forces India       Date:  2013-02-23

5.  Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome.

Authors:  Karin Mazodier; Valérie Marin; Daniela Novick; Catherine Farnarier; Stéphane Robitail; Nicolas Schleinitz; Véronique Veit; Pascale Paul; Menachem Rubinstein; Charles A Dinarello; Jean-Robert Harlé; Gilles Kaplanski
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

6.  Reactive hemophagocytic syndrome in a patient with polyarteritis nodosa associated with Epstein-Barr virus reactivation.

Authors:  Ikuko Hayakawa; Fumiaki Shirasaki; Hiroko Ikeda; Naoto Oishi; Minoru Hasegawa; Shinichi Sato; Kazuhiko Takehara
Journal:  Rheumatol Int       Date:  2006-04       Impact factor: 2.631

7.  Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.

Authors:  Alexander Kokkinos; Alexios Iliopoulos; Paraskevi Greka; Anna Efthymiou; Nicholas Katsilambros; Petros P Sfikakis
Journal:  Clin Rheumatol       Date:  2003-11-15       Impact factor: 2.980

Review 8.  Hemophagocytic syndromes and infection.

Authors:  D N Fisman
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

9.  Adult-onset Still's disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A.

Authors:  Jae-Hong Park; Joong Ho Bae; Yeon-Soo Choi; Hye-Soon Lee; Jae-Bum Jun; Sungsoo Jung; Dae-Hyun Yoo; Sang-Cheol Bae; Tae-Hwan Kim
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

10.  Fulminant hemophagocytic lymphohistiocytosis secondary to a reactivated EBV infection: a case report.

Authors:  Pantelis Antonodimitrakis; Cecilia Wassberg; Spyridon Gerovasileiou; Johan Back; Roger Hällgren; Björn Olsen
Journal:  Ups J Med Sci       Date:  2013-03       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.